scholarly journals c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays

2007 ◽  
Vol 96 (2) ◽  
pp. 329-335 ◽  
Author(s):  
S Garcia ◽  
J-P Dalès ◽  
J Jacquemier ◽  
E Charafe-Jauffret ◽  
D Birnbaum ◽  
...  
Keyword(s):  
Tissue Microarrays ◽  
Breast Carcinomas ◽  
Automated Quantification

scholarly journals Image Segmentation and Identification of Paired Antibodies in Breast Tissue

2014 ◽  
Vol 2014 ◽  
pp. 1-11 ◽  
Author(s):  
Jimmy C. Azar ◽  
Martin Simonsson ◽  
Ewert Bengtsson ◽  
Anders Hast
Keyword(s):  
Breast Tissue ◽  
Principal Component ◽  
Feature Space ◽  
Tissue Microarrays ◽  
Specific Protein ◽  
Blue Dye ◽  
Computationally Efficient ◽  
Automated Quantification ◽  
Human Protein Atlas ◽  
Low Dimensional

Comparing staining patterns of paired antibodies designed towards a specific protein but toward different epitopes of the protein provides quality control over the binding and the antibodies’ ability to identify the target protein correctly and exclusively. We present a method for automated quantification of immunostaining patterns for antibodies in breast tissue using the Human Protein Atlas database. In such tissue, dark brown dye 3,3′-diaminobenzidine is used as an antibody-specific stain whereas the blue dye hematoxylin is used as a counterstain. The proposed method is based on clustering and relative scaling of features following principal component analysis. Our method is able (1) to accurately segment and identify staining patterns and quantify the amount of staining and (2) to detect paired antibodies by correlating the segmentation results among different cases. Moreover, the method is simple, operating in a low-dimensional feature space, and computationally efficient which makes it suitable for high-throughput processing of tissue microarrays.

scholarly journals VGLL1 expression is associated with a triple-negative basal-like phenotype in breast cancer

2014 ◽  
Vol 21 (4) ◽  
pp. 587-599 ◽  
Author(s):  
María Ángeles Castilla ◽  
María Ángeles López-García ◽  
María Reina Atienza ◽  
Juan Manuel Rosa-Rosa ◽  
Juan Díaz-Martín ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative ◽  
Tissue Microarrays ◽  
The Cancer Genome Atlas ◽  
Luminal Progenitor ◽  
Breast Carcinomas ◽  
Luminal A ◽  
Her2 Positive ◽  
Cancer Subtypes ◽  
Grade 3

Vestigial-like 1 (VGLL1) is a poorly characterized gene encoding a transcriptional co-activator structurally homologous toTAZandYAPthat modulates the Hippo pathway inDrosophila. In this study, we examined the expression ofVGLL1and its intronic miRNA, miR-934, in breast cancer.VGLL1and miR-934 expression miRNA profiling was carried out on frozen samples of grade 3 invasive ductal carcinomas. VGLL1 protein was also examined in 433 sporadic andBRCA1-associated breast carcinomas on tissue microarrays. RNA-seq data from The Cancer Genome Atlas (TCGA) was used to confirm differences inVGLL1and miR-934 expression in different breast cancer subtypes, and to correlate their expression with that of other genes and miRNAs. Of 28 miRNAs differentially expressed in estrogen receptor (ER)-positive and ER-negative grade 3 breast carcinomas, miR-934 was most strongly upregulated in ER-negative carcinomas, and its expression was correlated with that ofVGLL1. NuclearVGLL1expression was observed in 13% of sporadic breast carcinomas, and whileVGLL1was only occasionally found in luminal A (0.70%) and B (5.60%) carcinomas, it was often expressed in HER2-positive (17%), triple-negative (TN) breast carcinomas (>40%) andBRCA1-associated TN carcinomas (>50%). These findings were confirmed in the TCGA dataset, which revealed positive associations with luminal progenitor genes (GABRP,SLC6A14,FOXC1,PROM1, andBBOX1) and strong negative correlations with ER-associated genes (ESR1,C6ORF211,GATA3, andFOXA1). Moreover,VGLL1expression was associated with reduced overall survival. In conclusion,VGLL1and miR-934 are mainly expressed in sporadic andBRCA1-associated TN basal-like breast carcinomas, and their coordinated expression, at least partially mediated by the direct modulation ofESR1, might be involved in the maintenance of a luminal progenitor phenotype.

Protein kinase CK2α subunit over-expression correlates with metastatic risk in breast carcinomas: Quantitative immunohistochemistry in tissue microarrays

2011 ◽  
Vol 47 (5) ◽  
pp. 792-801 ◽  
Author(s):  
Sophie Giusiano ◽  
Claude Cochet ◽  
Odile Filhol ◽  
Eve Duchemin-Pelletier ◽  
Véronique Secq ◽  
...  
Keyword(s):  
Protein Kinase ◽  
Tissue Microarrays ◽  
Breast Carcinomas ◽  
Over Expression ◽  
Quantitative Immunohistochemistry ◽  
Metastatic Risk

scholarly journals NKX3.1 is expressed in ER-positive and AR-positive primary breast carcinomas

2014 ◽  
Vol 67 (9) ◽  
pp. 768-771 ◽  
Author(s):  
Rebecca J Asch-Kendrick ◽  
Mark A Samols ◽  
Mohammed T Lilo ◽  
Andrea P Subhawong ◽  
Rajni Sharma ◽  
...  
Keyword(s):  
Hormonal Treatment ◽  
Tissue Microarrays ◽  
Suppressor Gene ◽  
Tumour Suppressor Gene ◽  
Her2 Status ◽  
Breast Carcinomas ◽  
Luminal A ◽  
Luminal B ◽  
Labelling Intensity ◽  
Er Positive

AimsNKX3.1 is an androgen-regulated tumour suppressor gene that is downregulated in prostate carcinoma. Immunohistochemistry for NKX3.1 is primarily specific for prostatic-derived tumours and tissue but is reported in a small number of breast carcinomas. NKX3.1 is also shown to inhibit estrogen receptor (ER) signalling in breast carcinoma models. Here, we investigate labelling of NKX3.1 in invasive ductal (IDC) and lobular (ILC) carcinomas of the breast with full characterisation of ER, progesterone receptor (PR), androgen receptor (AR) and Her2 status.MethodsTissue microarrays of 86 primary IDC and 37 ILC were labelled for NKX3.1. The IDC consisted of 20 luminal A, 7 luminal B, 14 Her2, and 45 triple negative carcinomas. The ILC consisted of 34 luminal A and 3 luminal B cases. NKX3.1 expression was scored as percentage nuclear labelling and labelling intensity.ResultsNuclear NKX3.1 labelling was seen in 2 IDC (2%) and 10 ILCs (27%). labelling intensity was weak in all cases (1–100% nuclear positivity). Positive NKX3.1 labelling was significantly associated with ILC (p<0.0001). NKX3.1 labelling was seen only in ER and AR-positive carcinomas, which showed a significant correlation (p=0.0003 and p=0.0079, respectively). Expression was not correlated with tumour stage, size, Her2 expression, presence of lymph node metastases or age.ConclusionsThis is the first study to evaluate NKX3.1 expression in breast carcinomas with known ER, PR, AR and Her2 status. Further studies are needed to evaluate what potential role NKX3.1 plays in ER and AR signalling and hormonal treatment response in breast carcinomas.

scholarly journals HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas

2006 ◽  
Vol 60 (9) ◽  
pp. 1001-1005 ◽  
Author(s):  
S. A. V. Ricardo ◽  
F. Milanezi ◽  
S. T. Carvalho ◽  
D. R. A. Leitao ◽  
F. C. L. Schmitt
Keyword(s):  
Monoclonal Antibody ◽  
Tissue Microarrays ◽  
The Novel ◽  
Breast Carcinomas ◽  
Rabbit Monoclonal Antibody ◽  
Invasive Breast Carcinomas

Molecular Classification of Breast Carcinomas Using Tissue Microarrays

2003 ◽  
Vol 12 (1) ◽  
pp. 27-34 ◽  
Author(s):  
Grace Callagy ◽  
Elena Cattaneo ◽  
Yataro Daigo ◽  
Lisa Happerfield ◽  
Lynda G. Bobrow ◽  
...  
Keyword(s):  
Molecular Classification ◽  
Tissue Microarrays ◽  
Breast Carcinomas

Developments in 3D Echocardiography

2009 ◽  
Vol 5 (2) ◽  
pp. 10 ◽  
Author(s):  
Jose Luis Zamorano ◽  
Keyword(s):  
3D Echocardiography ◽  
Resonance Imaging ◽  
Clinical Tool ◽  
3D Images ◽  
Processing Power ◽  
2D Echocardiography ◽  
Automated Quantification ◽  
Heart Cycle ◽  
Functional Mechanisms ◽  
Full Volume

3D echocardiography (3DE) will gain increasing acceptance as a routine clinical tool as the technology evolves due to advances in technology and computer processing power. Images obtained from 3DE provide more accurate assessment of complex cardiac anatomy and sophisticated functional mechanisms compared with conventional 2D echocardiography (2DE), and are comparable to those achieved with magnetic resonance imaging. Many of the limitations associated with the early iterations of 3DE prevented their widespread clinical application. However, recent significant improvements in transducer and post-processing software technologies have addressed many of these issues. Furthermore, the most recent advances in the ability to image the entire heart in realtime and fully automated quantification have poised 3DE to become more ubiquitous in clinical routine. Realtime 3DE (RT3DE) systems offer further improvements in the diagnostic and treatment planning capabilities of cardiac ultrasound. Innovations such as the ability to acquire non-stitched, realtime, full-volume 3D images of the heart in a single heart cycle promise to overcome some of the current limitations of current RT3DE systems, which acquire images over four to seven cardiac cycles, with the need for gating and the potential for stitch artefacts.

Sign in / Sign up

Export Citation Format

Share Document